Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Cymbalta was produced by Lilly and Shionogi.

Lilly projects 2008 profits up 14 per cent on 2007

The products include the companyís top-selling antipsychotic Zyprexa (olanzapine) and the newer antidepressant Cymbalta (duloxetine). ... Lilly expects Cymbalta to overtake Zyprexa as its best-selling US product in 2008.

FDA approves Cymbalta for maintenance of major depression

The trial assessed 533 patients with major depression, who received 60 mg of Cymbalta once daily. ... In Q3 FY07, sales of Cymbalta rose 47 per cent to reach USD 513.2m.

A bit too green

Cymbalta and diclomax SR 2007 - 98%. For depression and arthritic pain Rather unfortunately, the Cymbalta ad and the Diclomax SR ad appeared on the same spread in GP.

News in brief, April 18, 2007

Sales increased 14 per cent to rest at USD 4.2bn. Sales for Alimta (pemetrexed), Byetta (exenatide), Cialis (tadalafil), Cymbalta/ Yentreve (duloxetine ), Forteo (teriparatide), Strattera (atomoxetine), Symbyax (olanzapine/ fluoxetine) and Xigris

Global survey shows neuropathic pain under-diagnosed and under-served

The traditional. The NeP market is being driven by growing demand for Pfizer's Lyrica (pregabalin) and Eli Lilly's antidepressant, Cymbalta (duloxetine), as well as Teikoku Seiyaku's Lidoderm/Versatis ... Lilly's SNRI-inhibitor Cymbalta, which is

[ Previous 5 results ] 8 9 10 11 12

COVID-19 Updates and Daily News

Featured jobs


Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....